- Khiron was the sole cannabis company to present during the
four-day symposium organized by the Mexican College of Internal
Medicine
- Event participation builds upon Khiron's relationship with the
Mexican College of Internal Medicine, a leading association of
internal medicine specialists that previously endorsed the company
in 2018
- Conference attendees included over 2000 leading specialists,
physicians and healthcare professionals from across Mexico
TORONTO, July 8, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV:KHRN, OTCQB:KHRNF), a
cannabis company with core operations in Latin America announced today its
participation in the XLIV International Course of Internal Medicine
conference, which took place from July
3-6 in Monterrey, Mexico.
Organized by the Mexican College of Internal Medicine, Khiron was
the only cannabis company to participate in this year's conference,
where it joined over 2000 physicians and medical specialists to
inform, educate and discuss medical cannabis knowledge and
developments.
On July 3rd, Khiron opened the
conference with a one-hour session covering global research and
insight on the safe and responsible prescription of medical
cannabis, presented by Dr. Maria Fernanda
Arboleda, International Director of Medical Services at
Khiron Life Sciences and medical cannabis expert. The Company also
hosted a booth at the conference from July
4-6, where attendees had the opportunity to learn about the
Khiron brand, explore its products, and engage in interactive
discussion with Khiron's medical team.
Luis Chaves, Khiron's country
manager for Mexico, stated: "At
Khiron, we have been continually committed to helping doctors and
health care professionals provide safe and effective medical
cannabis treatment options. As one of Mexico's foremost platforms for advancing the
conversation around medical cannabis, our participation in the XLIV
International Course of Internal Medicine furthers our stated
mission to increase awareness on the benefits of cannabis for
medical use, and to introduce medicinal cannabis products across
Mexico and Latin America."
Combined with Khiron's ongoing medical education efforts to
engage physicians across the country, the
Company's presence at the XLIV International Course of
Internal Medicine conference further builds upon its close
relationship with medical associations and health care
professionals across the LatAm region. Khiron has previously
received the endorsement of the Mexican College of Internal
Medicine for KhironMed, the Company's Medical Cannabis Symposium
held in Mexico City last
February 2019, as well as for its
schedule of medical education symposium and activities taking place
in Mexico this year.
Dr. Roberto Lopez, president of
the Mexican College of Internal Medicine, commented: "As scientific
research continues to support the use of cannabis-based products
for various medical conditions, the XLIV International Course of
Internal Medicine aims to train health leaders in the safe use and
prescription of medicinal cannabis. We were incredibly excited to
have Khiron join us and participate in this year's conference."
About the Mexican College of Internal
Medicine
The Mexican College of Internal Medicine is a
medical institution that seeks to consolidate and guide the
presence of internal medicine in Mexico. Among its main
objectives are to promote, foster, advise and carry out academic
research and continuing education activities that encourage the
development and highest level of internal medicine, as well as to
provide access to experts in financial and legislative issues.
For further information visit https://www.cmim.org/
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. In May 2018, Khiron
listed on the TSXV, becoming the first Colombian based medical
cannabis company to trade on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
To be added to the distribution list, please email
khiron@kcsa.com with "Khiron" in the subject line.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Further information in respect of the Company can
be found at www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-leads-cannabis-education-at-xliv-international-course-of-internal-medicine-reaching-over-2-000-medical-specialists-in-mexico-300880509.html
SOURCE Khiron Life Sciences Corp.